Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Diabetes AND insulin glargine AND insulin aspart

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    59 result(s) found for: Diabetes AND insulin glargine AND insulin aspart. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2017-003219-20 Sponsor Protocol Number: NN9535-4386 Start Date*: 2018-09-13
    Sponsor Name:Novo Nordisk A/S
    Full Title: Effect of semaglutide once-weekly versus insulin aspart three times daily, both as add on to metformin and optimised insulin glargine (U100) in subjects with type 2 diabetes A 52-week, multi-ce...
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) SI (Completed) EE (Completed) BG (Completed) LV (Completed) PL (Completed) GR (Completed) DE (Completed) CZ (Completed) LT (Completed) PT (Completed) ES (Completed) HR (Completed) HU (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2009-012923-27 Sponsor Protocol Number: NN1250-3770 Start Date*: 2011-12-09
    Sponsor Name:Novo Nordisk A/S
    Full Title: Begin™: Flex T1. A 26-week trial investigating the dosing flexibility, efficacy and safety of NN1250 in subjects with type 1 diabetes with a 26-week extension.
    Medical condition: Type 1 diabetes
    Disease: Version SOC Term Classification Code Term Level
    12.0 10045228 Type I diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) BE (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-004768-12 Sponsor Protocol Number: NN5401-4266 Start Date*: 2016-08-10
    Sponsor Name:Novo Nordisk A/S
    Full Title: A 38 week trial comparing effect and safety of insulin degludec/insulin aspart vs. insulin glargine plus insulin aspart in subjects with type 2 diabetes treated with basal insulin with or without o...
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2020-000474-16 Sponsor Protocol Number: NN1436-4480 Start Date*: 2020-11-19
    Sponsor Name:Novo Nordisk A/S
    Full Title: A 26-week trial comparing the effect and safety of once weekly insulin icodec and once daily insulin glargine 100 units/mL, both in combination with bolus insulin with or without non-insulin anti-d...
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-005777-35 Sponsor Protocol Number: NN1250-3582 Start Date*: 2009-08-05
    Sponsor Name:Novo Nordisk A/S
    Full Title: A 52-week randomised, controlled, open label,multicentre, multinational treat-to target trial comparing efficacy and safety of SIBA and insulin glargine both administered once daily in a basal-bolu...
    Medical condition: type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IE (Completed) ES (Completed) IT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2010-024051-93 Sponsor Protocol Number: NN1218-3853 Start Date*: 2013-05-23
    Sponsor Name:Novo Nordisk A/S
    Full Title: Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination with Insulin Glargine and Metformin in Adults with Type 2 Diabetes
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2014-003708-62 Sponsor Protocol Number: BIAsp-4157 Start Date*: 2015-06-03
    Sponsor Name:Novo Nordisk A/S
    Full Title: A 32-week randomised, multinational, treat-to-target, open label, parallel group comparison of stepwise insulin intensification of biphasic insulin aspart (BIAsp) 30 and basal-bolus therapy with in...
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2020-005309-18 Sponsor Protocol Number: NN1535-4593 Start Date*: 2021-11-30
    Sponsor Name:Novo Nordisk A/S
    Full Title: A 52 week study comparing the efficacy and safety of once weekly IcoSema and daily insulin glargine 100 units/mL combined with insulin aspart, both treatment arms with or without oral anti diabetic...
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    21.1 10027433 - Metabolism and nutrition disorders 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) HU (Completed) CZ (Completed) FR (Completed) SI (Completed)
    Trial results: View results
    EudraCT Number: 2010-024049-53 Sponsor Protocol Number: NN1218-3852 Start Date*: 2013-07-16
    Sponsor Name:Novo Nordisk A/S
    Full Title: Efficacy and Safety of FIAsp compared to insulin aspart both in Combination with insulin detemir in Adults with Type 1 Diabetes
    Medical condition: Diabetes Mellitus, Type 1
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004861 10045228 Type I diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) HU (Completed) CZ (Completed) GB (Completed) DE (Completed) PL (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2008-005774-13 Sponsor Protocol Number: NN1250-3583 Start Date*: 2009-07-24
    Sponsor Name:Novo Nordisk A/S
    Full Title: A 52 week randomised, controlled, open label, multicentre, multinational, parallel, treat-to-target trial comparing efficacy and safety of SIBA and insulin glargine both administered once daily in ...
    Medical condition: type 1 diabetes
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045228 Type I diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2004-000086-35 Sponsor Protocol Number: NN304-1430 Start Date*: 2004-11-01
    Sponsor Name:Novo Nordisk Farma Oy
    Full Title: A one-year, multi-national, open-labelled, parallel-group, 2:1 randomised treat-to-target trial comparing efficacy and safety of insulin detemir with insulin glargine using a basal-bolus regimen wi...
    Medical condition: Type 1 diabetes
    Disease: Version SOC Term Classification Code Term Level
    7.0 10012608 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2009-015816-17 Sponsor Protocol Number: NN1250-3667 Start Date*: 2010-07-20
    Sponsor Name:Novo Nordisk A/S
    Full Title: An extension trial to NN1250-3582 comparing safety and efficacy of NN1250 and insulin glargine, both with insulin aspart as meal-time insulin ± OADs in type 2 diabetes
    Medical condition: Type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    12.1 10067585 Type 2 diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) DE (Completed) ES (Completed) IT (Completed) SK (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2010-018974-19 Sponsor Protocol Number: ANA-3786 Start Date*: 2010-09-03
    Sponsor Name:Novo Nordisk A/S
    Full Title: A randomised, controlled, open label, multicentre, multinational, treat-to-target trial investigating the efficacy and safety of intensification with addition of bolus insulin aspart in subjects wi...
    Medical condition: Type 2 Diabetes
    Disease: Version SOC Term Classification Code Term Level
    12.1 10067585 Type 2 diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) SI (Completed)
    Trial results: View results
    EudraCT Number: 2017-003370-13 Sponsor Protocol Number: LPS15017 Start Date*: 2018-10-10
    Sponsor Name:Sanofi-Aventis Groupe
    Full Title: A multi-center open-label parallel group randomized controlled trial to compare iGlarLixi versus premixed insulin in patients with type 2 diabetes who have failed to achieve glycemic control with b...
    Medical condition: Patients with Type 2 Diabetes who have failed to achieve glycemic control with basal insulin and oral antidiabetic agents(OADs)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) AT (Completed) ES (Completed) SE (Completed) BG (Completed) GR (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2009-015755-24 Sponsor Protocol Number: NN1250-3644 Start Date*: 2010-04-08
    Sponsor Name:Novo Nordisk A/S
    Full Title: An extension trial to trial NN1250-3583 comparing safety and efficacy of NN1250 with insulin glargine, both with insulin aspart as meal-time insulin, in type 1 diabetes
    Medical condition: Type 1 diabetes
    Disease: Version SOC Term Classification Code Term Level
    12.1 10067584 Type 1 diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-017814-56 Sponsor Protocol Number: NN5401-3599 Start Date*: 2011-01-31
    Sponsor Name:Novo Nordisk A/S
    Full Title: A 26-week, randomised, open-label, multinational, treat-to-target trial comparing efficacy and safety of insulin degludec/insulin aspart once daily (OD) and insulin glargine OD both in combination ...
    Medical condition: Type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    12.1 10067585 Type 2 diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2004-001287-49 Sponsor Protocol Number: HMR1964A/3504 Start Date*: 2004-12-21
    Sponsor Name:Sanofi-Aventis Deutschland GmbH
    Full Title: 52-week, open, randomized, multinational, multicenter clinical trial comparing insulin glulisine in combination with insulin glargine in an intensified insulin regimen to a two-injection convention...
    Medical condition: Diabetes mellitus type 2
    Disease: Version SOC Term Classification Code Term Level
    10012613
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) CZ (Completed) ES (Completed) GB (Completed) SK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-015742-34 Sponsor Protocol Number: APIDR_L_04717 Start Date*: 2009-12-11
    Sponsor Name:sanofi-aventis
    Full Title: Better Accepance of a Singe injection Apidra (insulin glulisine) Added to once daily Lantus (insulin glargine) versus twice daily Premixed insulin in a real Life Use Setting.
    Medical condition: Type 2 Diabetes Mellitus
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2004-000087-27 Sponsor Protocol Number: NN304-1431 Start Date*: 2004-07-04
    Sponsor Name:Novo Nordisk Farma Oy
    Full Title: A one-year, multi-national, open-labelled, parallel-group, 2:1 randomised treat-to-target trial comparing efficacy and safety of insulin detemir with insulin glargine using a basal-bolus regimen wi...
    Medical condition: Type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    7.0 10012613 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2011-000829-73 Sponsor Protocol Number: I4L-MC-ABEB Start Date*: 2011-09-12
    Sponsor Name:Eli Lilly and Company
    Full Title: A Prospective, Randomized, Open-Label Comparison of a Long-Acting Basal Insulin Analog LY2963016 to Lantus® in Combination with Mealtime Insulin Lispro in Adult Patients with Type 1 Diabetes Mel...
    Medical condition: type 1 diabetes
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10067584 Type 1 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) GR (Completed) HU (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 13 09:41:41 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA